Wednesday, March 27, 2024
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has taken a significant stride forward in improving surgical care for patients with neurological disorders. The company has announced the launch of its OneRF™ Ablation System, which has received clearance from the FDA under the 510(k) designation. This innovative system enables the creation of radiofrequency (RF) lesions in nervous tissue for functional neurosurgical procedures.
The OneRF™ Ablation System represents NeuroOne's inaugural therapeutic device and is the third FDA 510(k)-cleared product in its lineup. It complements the company's existing portfolio of electrode technology, which includes solutions for both diagnostic brain mapping procedures and RF ablation using the same sEEG electrode.
In addition to the OneRF™ Ablation System, NeuroOne's FDA-cleared devices encompass the Evo® cortical and sEEG electrode product lines. These are primarily utilized for recording brain electrical activity for periods of less than 30 days.
The global brain ablation market is experiencing rapid growth and is estimated to exceed $100 million. NeuroOne is poised to address significant unmet clinical needs within this large patient population.
Source: globenewswire.com
